Profile data is unavailable for this security.
About the company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
- Revenue in USD (TTM)55.70m
- Net income in USD-414.64m
- Incorporated2017
- Employees483.00
- LocationBeam Therapeutics Inc238 Main StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 327-8775
- Fax+1 (302) 655-5049
- Websitehttps://beamtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.23bn | 51.00 | -- | 3.86 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.33bn | 287.00 | -- | 16.41 | -- | 21.33 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.46bn | 627.00 | -- | 4.92 | -- | 10.25 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.51bn | 483.00 | -- | 2.59 | -- | 45.05 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Adaptive Biotechnologies Corp | 252.75m | -79.61m | 2.51bn | 619.00 | -- | 12.29 | -- | 9.95 | -0.5381 | -0.5381 | 1.65 | 1.34 | 0.4818 | 6.50 | 5.90 | 408,326.30 | -15.17 | -21.92 | -18.12 | -24.85 | 71.84 | 64.77 | -31.49 | -119.25 | 3.26 | -55.47 | 0.3923 | -- | 5.10 | 16.04 | 29.19 | -- | -20.03 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.56bn | 95.00 | -- | 6.66 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.64bn | 385.00 | -- | 35.84 | -- | 6.05 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.65bn | 118.00 | -- | 8.34 | -- | 273.58 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.67bn | 240.00 | -- | 3.41 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.76bn | 824.00 | 91.96 | 2.19 | 52.30 | 5.57 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.78bn | 143.00 | -- | 7.64 | -- | 39.33 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.79bn | 131.00 | -- | 2.55 | -- | 12.96 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 2.87bn | 224.00 | -- | 6.56 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 2.88bn | 136.00 | -- | 5.15 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
Data as of Feb 06 2026. Currency figures normalised to Beam Therapeutics Inc's reporting currency: US Dollar USD
64.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 30 Sep 2025 | 11.04m | 10.88% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 10.13m | 9.98% |
| Farallon Capital Management LLCas of 30 Sep 2025 | 10.06m | 9.92% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.38m | 8.26% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.78m | 6.68% |
| Amova Asset Management Americas, Inc.as of 30 Sep 2025 | 4.83m | 4.76% |
| Amova Asset Management Co., Ltd.as of 31 Dec 2025 | 4.41m | 4.35% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 4.01m | 3.95% |
| Bellevue Asset Management AGas of 30 Sep 2025 | 2.89m | 2.85% |
| Kynam Capital Management LPas of 30 Sep 2025 | 2.52m | 2.48% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
